Inflammatix is focused on developing innovative diagnostic tests that leverage the immune response to improve the management of patients suspected of acute infections and sepsis. Their flagship product, the TriVerity Test, is designed to provide rapid and clinically actionable insights by measuring the expression levels of 29 genes related to the innate immune response in blood samples. Utilizing advanced machine learning algorithms, the test can deliver results within approximately 30 minutes, helping physicians determine whether a patient has a bacterial or viral infection and whether they require intensive care. This approach addresses a critical need in emergency medicine, where accurate and timely diagnosis can significantly impact patient outcomes.

The company is also pioneering research into sepsis subtypes, or "endotypes," which may lead to more personalized treatment strategies. By analyzing transcriptomic data, Inflammatix aims to classify patients into distinct groups based on their immune response profiles, similar to how breast cancer is categorized by specific biomarkers. This research is part of a broader effort to apply precision medicine principles to sepsis, potentially improving treatment efficacy and patient survival rates. Inflammatix collaborates with various stakeholders, including drug and device companies, to identify patients who may benefit from targeted therapies, thereby advancing the field of sepsis management.

United States

Inflammatix is developing an innovative point-of-care instrument platform to be used with a test to aid in the diagnosis of acute infection and sepsis by harnessing the immune system to deliver advanced immune response diagnostics. Our test rapidly informs the clinician about the likelihood of bacterial or viral infection and the need for ICU level care in the emergency department. Faster results may translate into more timely and appropriate therapy and level of care decisions. 

*Products in development, are not for sale, and do not have marketing approval or clearance from regulatory authorities in any jurisdiction.

Inflammatix

Company Details